论文部分内容阅读
目的:探讨小剂量利妥昔单抗注射液(通用名为利妥昔单抗注射液)联合环孢素A治疗难治性特发性血小板减少性紫癜(简称难治性ITP)的疗效。方法:38例诊断为难治性ITP患者随机分为观察组和对照组,观察组采用小剂量利妥昔单抗注射液联合环孢素A治疗,对照组采用大剂量地塞米松冲击联合硫唑嘌呤治疗,并评估两组患者的近期及远期疗效和副作用。结果:观察组的近期及远期疗效优于对照组,2组间差异有显著性(P<0.05),除肝功能方面,不良反应的其他指标的比较,2组间差异无显著性(P>0.05)。结论:小剂量利妥昔单抗注射液联合环孢素A可作为难治性ITP的有效治疗手段之一。
Objective: To investigate the efficacy of low dose rituximab injection (commonly known as rituximab injection) combined with cyclosporin A in the treatment of refractory idiopathic thrombocytopenic purpura (referred to as refractory ITP). Methods: Thirty-eight patients with refractory ITP were randomly divided into observation group and control group. The observation group was treated with low dose rituximab injection combined with cyclosporin A. The control group was treated with high dose dexamethasone combined with thiazole Purine treatment, and assess the short-term and long-term efficacy and side effects in both groups. Results: The short-term and long-term efficacy of the observation group was better than that of the control group, with significant difference between the two groups (P <0.05). There was no significant difference between the two groups except for liver function and other indicators > 0.05). Conclusions: Low dose rituximab injection combined with cyclosporin A can be used as an effective treatment for refractory ITP.